{
  "slug": "broad-institute",
  "name": "Cancer Cell Line Encyclopedia (CCLE)",
  "description": "The Cancer Cell Line Encyclopedia (CCLE) is a collaborative project primarily between the Broad Institute and Novartis Institutes for Biomedical Research. It aims to conduct detailed genetic and pharmacologic characterization of a large panel of human cancer cell lines, develop integrated computational analyses to link pharmacologic vulnerabilities with genetic/expression patterns, and translate these findings into cancer patient stratification and drug discovery.",
  "url": "https://optimly.ai/brand/broad-institute",
  "websiteUrl": null,
  "logoUrl": "https://logo.clearbit.com/https://sites.broadinstitute.org/ccle",
  "baiScore": 47,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": "Incumbent",
  "archetype_status": "active",
  "category": "Biomedical Research",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-08-02T00:03:32.981Z",
  "verifiedVitals": {
    "website": "https://sites.broadinstitute.org/ccle",
    "founded": "2008",
    "headquarters": "Not specified in context",
    "pricing_model": "Publicly accessible data, implying a research-driven, open-access model, likely supported by grants and institutional funding.",
    "core_products": "Comprehensive genomic, transcriptomic, metabolomic, proteomic, and pharmacologic datasets for a large panel of human cancer cell lines; scientific publications and research findings.",
    "key_differentiator": "The large-scale, systematic, and multi-omics characterization of approximately 1000 cancer cell lines, providing a deeply annotated resource for predictive modeling of anticancer drug sensitivity and foundational insights into cancer biology.",
    "target_markets": "Cancer researchers, drug developers, oncologists, academic institutions, pharmaceutical companies, and the broader biomedical scientific community.",
    "employee_count": "Not specified in context",
    "funding_stage": "Research grants and institutional collaboration (e.g., Novartis Institutes for Biomedical Research)",
    "subcategory": "Cancer Genomics"
  },
  "intentTags": {
    "problemIntents": [
      "Small-scale, in-house cell line characterization: Researchers could conduct genetic and pharmacological screens on a limited number of cancer cell lines within their own labs, similar to pre-CCLE effo",
      "Relying on traditional, limited cell line models: As highlighted by the 'Motivations' section, before CCLE, investigations were 'limited to a few commonly used cell lines or at most the 60 cell lines "
    ],
    "solutionIntents": [
      "Cancer Cell Line Encyclopedia",
      "Broad Institute CCLE",
      "CCLE drug sensitivity data",
      "Utilizing other public or proprietary datasets: Researchers might rely on other smaller or more specialized public cancer cell line databases, or access proprietary datasets from pharmaceutical compan"
    ],
    "evaluationIntents": []
  },
  "timestamp": 1785753755116
}